Indaptus Therapeutics is trading at $2.40, up +6.33%, with no verified catalyst identified for the rise. - No fresh company announcement explaining the October 15 move surfaced in the search; the private-placement deadline extension to October 16 was announced earlier, not today. - Broader markets were under pressure after hotter-than-expected U.S. inflation revived rate concerns. Reuters reported falling U.S. stocks and continued selling pressure in Asian markets, but that backdrop does not explain the stock’s gain.